Tocilizumab and Systemic Sclerosis

Author: James Radke, PhD
Date Published: June-2015
Source: Rare Disease Report

It’s a busy week for Genentech and systemic sclerosis researchers. First, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation status to tocilizumab (Actemra) for treating patients with systemic sclerosis, or scleroderma.1 The designation should expedite the development and review of tocilizumab for this rare condition. Second, data from the phase 2 study that led to the Breakthrough Designation is being presented at EULAR 2015 this week as well. The developers of tocilizumab, Genentech also announced they have begun a phase 3 study to test the safety and efficacy of tocilizumab in patients with systemic sclerosis.